Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...

chief medical officer at Merck. The current study, named HYPERION, enrolled about 300 newly diagnosed patients PAH patients who were randomly chosen to receive Winrevair along with a background ...

Merck (MRK) announced the U.S. FDA has accepted for priority review a supplemental new drug application seeking approval of Welireg, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, for ...

Merck (MRK) announced that the board of directors ... The board also authorized an additional $10B of treasury stock purchases with no time limit for completion, the company announced.

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter ...

A Merck spokesman has said the allegations have no merit. Mr. Kennedy would receive a potentially significant sum if Merck settles the cases or if there is a verdict against the drug company in ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...

He says, if confirmed, he can still earn referral fees from a firm suing Merck. In 2020 ... Public health researchers and doctors said there was no evidence that the vaccine, Gardasil, was ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans ... over the next two to three years, there’s no reason we shouldn’t aspire to grow through ...